## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.07 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($199.96)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Paxton Secures Major Win Against Johnson & Johnson and Kenvue**
- Source: Texas Border Business | 20251208T191740 | Neutral | Relevance: 99%
-  Attorney General Ken Paxton secured a legal victory against Johnson & Johnson and Kenvue, obtaining a Temporary Restraining Order for their operations in Texas without required registrations. The companies failed to comply with the Texas Business Organizations Code, which mandates foreign entities to register before conducting business in the state. Paxton emphasizes his commitment to holding powerful corporations accountable and protecting Texans' well-being over corporate greed.

**2. Early use of CARVYKTI shows lasting remissions in multiple myeloma**
- Source: PharmaTimes | 20251208T140824 | Bullish | Relevance: 98%
- Johnson & Johnson has released updated results from the phase 3 CARTITUDE-4 study, indicating that CARVYKTI (cilta-cel) can achieve durable, treatment-free remissions in relapsed or refractory multiple myeloma patients as early as second-line therapy. The study showed that 80% of standard-risk patients treated with cilta-cel after first relapse remained progression and treatment-free at 2.5 years. These findings support the potential for cilta-cel to fundamentally shift the trajectory of multiple myeloma and extend patients' lives.

**3. Johnson & Johnson $JNJ Shares Purchased by Stamos Capital Partners L.P.**
- Source: MarketBeat | 20251210T123153 | Bullish | Relevance: 98%
-  Stamos Capital Partners L.P. significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 58.7% in Q2 2025, now holding 65,088 shares valued at $9.94 million, making J&J its tenth largest holding. Wall Street analysts have shown positive sentiment, with an average price target of $203.15 and a "Moderate Buy" rating for the pharmaceutical giant. Johnson & Johnson's latest financials include a market cap of over $481 billion, a PE ratio of 19.3, and a quarterly dividend of $1.30 per share.

**4. JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?**
- Source: Finviz | 20251210T134939 | Somewhat-Bullish | Relevance: 98%
-  This article compares Johnson & Johnson (JNJ) and Pfizer (PFE), two prominent blue-chip pharmaceutical companies, to determine which offers a better investment opportunity. It delves into their fundamental strengths, growth prospects, and challenges, including patent expirations and the impact of the Medicare Part D redesign. Ultimately, the analysis suggests J&J is the better pick due to its diversified business model, strong pipeline, and consistent financial performance, despite Pfizer's attractive valuation and dividend yield.

**5. Health changes everything: Europeâ€™s smart investment**
- Source: Economist Impact | 20251209T090851 | Bullish | Relevance: 98%
- Europe faces demographic challenges including an aging population and rising chronic disease, which threaten economic growth. The article argues that treating healthcare as an investment rather than a cost can drive productivity, competitiveness, and prosperity, citing economic benefits that far outweigh the initial investment. It highlights how past austerity measures weakened health systems and calls for political decision-makers to prioritize long-term health outcomes and innovation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Insider selling cluster: $4.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 17.9x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $497.6B |
| Beta | 0.35 |
| 52W Range | $140.68 - $207.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.9 |
| Current P/E | 19.0 |
| YoY Growth | 6.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.4% (minimal 5-day change). Below STRENGTH zone by 4.4pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.63), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.37% (CS: 50) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.209x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $206.54
- **Stop Loss:** $199.96 (3.2% risk)
- **Target:** $219.70 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $15,490.50
- **Portfolio %:** 15.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*